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Abstract 
 
Objective 
Some perceived medication side effects may be ‘normal’ symptoms that patients 
misattribute to the medication. Using an analogue approach, we tested if medication beliefs 
predict whether participants misattribute a headache as a side effect and subsequently intend to 
stop medication. 
 
Methods 
 
We recruited 690 participants, 223 reporting a past asthma diagnosis. They received 
information about asthma and Molair, a fictitious asthma treatment modelled on a licensed 
treatment (montelukast). We varied the description of efficacy and side effects (which did not 
include headache). Pre-exposure to this information, participants completed the Beliefs about 
Medicine Questionnaire (BMQ)-General and the Perceived Sensitivity to Medicines Scale 
(PSM), post-exposure they completed the BMQ-Specific. Participants were asked to imagine 
they experienced a headache while taking Molair. Finally, they rated whether the headache was 
a side effect (misattribution) and if they would stop taking Molair (behavioural intention). 
 
Results 
Nearly a quarter (170) of participants misattributed the headache to Molair and 69 (10%) 
subsequently intended to stop Molair. Both outcomes were predicted by general and specific 
medication beliefs. Odds of misattribution (m) and behavioural intention (i) increased with higher 
General Harm (ORm=1.90, ORi=2.72), General Overuse (ORm=1.74, ORi=1.56) and Molair 
Concern beliefs (ORm=1.52, ORi=1.78, all p<.01), but decreased with General Benefit 
(ORm=0.72, ORi=0.53) and Molair Necessity beliefs (ORm=0.72, ORi=0.70, all p<.05). 
 
Conclusion 
Symptom misattribution and subsequent intentions to stop Molair were predicted by pre-
exposure beliefs about medicines in general and post-exposure beliefs about Molair. Patients 
with negative medication beliefs may be prone to misattribute symptoms and subsequently stop 
medication. 
 
Key words: adherence, asthma, attribution, beliefs about medicines, nocebo, side effects  
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Highlights:  
 We tested if medication beliefs predict misattribution of symptoms as side effects 
 Participants imagined they took a fictitious asthma medication and had a headache. 
 General and specific medication beliefs predicted misattribution of the headache. 
 Misattribution and negative beliefs increased intention to stop medication. 
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Introduction  
The prescription of a medicine is one of the most common interventions in affluent healthcare 
systems. Appropriate medication use is crucial to the management of most long-term conditions 
that account for the majority of health spending (1). But, the capacity of medication to improve 
health is compromised by adverse effects and nonadherence (2, 3). People who experience 
(and sometimes merely anticipate) side effects are prone to nonadherence (4, 5), and 
consequently less likely to experience the full benefit from their treatment, with implications for 
morbidity, mortality and healthcare utilization. For patients who take their medication, side 
effects add to the burden of disease and treatment (6), increase anxiety and reduce quality of 
life (7, 8). Problems linked to medication side effects in ambulatory (e.g. treatment changes, 
additional doctor visits) and non-ambulatory settings (e.g. longer hospitalization) were estimated 
at over $170 billion per year in the US alone (9). 
 
Understanding determinants of side effects therefore has implications for patients and 
healthcare systems. Side effects are often caused by specific pharmacological effects of 
medication. For example, aspirin inhibits prostaglandin pathways in the stomach, which can 
lead to gastric erosion (10). Psychological factors such as expectations and conditioning (11) 
also contribute to side effects. Around 20-25% of chemotherapy patients experience nausea or 
vomiting before drug administration (12, 13), indicating the importance of non-pharmacological 
factors in side effect experiences. 
 
The misattribution of symptoms arising due to disease, everyday activities or normal bodily 
variations, as side effects may be another psychological process contributing to side effect 
reports (14, 15). Symptoms like dizziness, headache and fatigue are frequently reported as 
“side effects” by patients receiving placebo in randomized controlled trials (16-19) and are 
common in healthy individuals not taking medication (20-22). 
 
In this paper we test whether cognitive representations of specific medications and 
pharmaceuticals in general (23-26) influence the attribution of symptoms as side effects. 
Specific medication beliefs are the salient beliefs influencing engagement with a specific 
treatment for a given condition. They are operationalised in the Necessity Concerns Framework 
(27, 28) which posits that evaluations of prescribed medicines are influenced by judgment of 
personal necessity for treatment relative to concerns about potential harm (29). These 
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evaluations are influenced by general ‘social representations’ of pharmaceuticals as a class of 
treatment (e.g. whether pharmaceuticals are fundamentally harmful, addictive chemicals that 
are over-prescribed by doctors (23, 26, 30)), representations of the health threat (e.g. illness 
representations) and somatic experiences and attributions (e.g. whether a symptom is attributed 
to illness or medication) (25, 31, 32). Symptom experiences and attributions are therefore a key 
determinant of how we think about and act upon illnesses (33-35). Medication beliefs have been 
linked to side effect reports in prospective clinical samples with rheumatoid arthritis (36), 
depression (37), and HIV/AIDS (38). A tendency for individuals with negative beliefs about 
medicine to attribute everyday ‘normal’ symptoms to their medication could contribute to these 
associations.  
 
In this study, we asked participants to imagine taking a fictitious asthma medication and 
then experiencing a headache (not listed as a side effect of the medication). We probed whether 
participants attributed the headache as a side effect and subsequently intended to stop the 
medication. Although this was an analogue study, we wanted to make the scenario presented 
as concrete and believable to participants as possible. We therefore chose a common disease, 
asthma (39), so that we were could recruit participants online who either had asthma or were 
familiar with it. Likewise, we chose headache, a common ‘everyday’ symptom and side effect 
(22, 40, 41) to probe symptom attribution. In addition, side effects and side effect-related 
discontinuation of asthma medication, and headaches to placebo have all been reported in 
asthma (42, 43). Our primary hypothesis was that participants with negative medication beliefs 
would be more likely to: (1) Misattribute the headache symptom as a side effect and (2) 
subsequently intend to stop the medication. 
We systematically varied information about the fictitious medication, presenting it as highly or 
moderately effective and having either frequent or rare side effects. We expected the variation 
of the patient information to influence people’s specific beliefs about the medication (e.g. 
increased concerns for participants randomized to high side effect frequency information). We 
also wanted to check whether any effect of beliefs on misattribution and intention were robust 
across this information variation. We explored whether the hypothesized relationships were 
similar for participants with and without self-reported previous asthma diagnosis and persisted 
when controlling for negative affect as a potential confounder. Because we were measuring 
beliefs about a fictitious medication, we also checked that the associations between general and 
specific beliefs were consistent with theoretical predictions (24) and previously reported 
associations (30).  
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Method 
Data was collected in three consecutive waves. Within each wave, participants were 
randomised to different descriptions of the efficacy and safety of the fictitious medication. In all 
waves participants completed validated measures of medication beliefs and the symptom 
attribution vignette. Affect was assessed in wave three.  
 
Participants and Recruitment 
We included individuals over 18, with and without self-reported past asthma diagnosis. 
Only one response was allowed per participant (across the three waves). Participants were 
recruited on online job boards (e.g. Amazon MTurk, Crowd Guru, DailySurveyPanel) where 
subscribers complete surveys for small monetary rewards (around $0.30 in this study), and an 
online research website (Psychological Research on the Net). This sampling approach has 
demonstrated reliability in studies of decision–making, personality and health (44-46).  
 
Materials 
Asthma and Molair information 
Participants read information about asthma (see Appendix A) structured according to 
Leventhal’s Common Sense Model of illness representations (47, 48). It described asthma 
causes (airway inflammation and sensitization), triggers (e.g. exercise, pollen), likely 
consequences, and asthma management (e.g. medicines and lifestyle changes) and asthma 
symptoms (e.g. difficulty breathing, wheezing) and their episodic nature.  
Participants were randomized to one of four written patient information leaflets (PILs) of 
the fictitious asthma drug Molair (see Appendix B), modelled on the existing asthma medication, 
montelukast (49):  
1) The “High Efficacy PIL” stated that Molair is highly effective ‘86.6% of patients reported 
a strong improvement in daytime asthma symptoms’ and contained no information about the 
frequency of side effects.  
2) The “Moderate Efficacy PIL” stated that Molair is less effective, ‘53.2% of patients 
reported a small improvement’ and contained no information about the frequency of side effects. 
3) The “Low Side Effect Frequency PIL” contained general efficacy information “Molair can 
be effective in preventing asthma symptoms.” and stated that side effects were rare “in less than 
1 in 100 people”.  
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4) The “High Side Effect Frequency PIL” contained general efficacy information “Molair 
can be effective in preventing asthma symptoms.” and stated that side effects were frequent “in 
more than 45 out of 100 people”. 
 
All four PILs contained the same list of 8 side effects, presented in randomized order. Headache 
was not listed as one of Molair’s side effects. 
The information was in line with published montelukast efficacy data (50-52) and reported side 
effect rates to montelukast relative to placebo (53) (low frequency) and placebo in randomized 
controlled trials (54-56) (high frequency).  
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Measures 
 
Symptom misattribution and behavioural intention measures 
Participants read the following scenario: “Imagine you are suffering from asthma. You 
have been taking one 4mg tablet of Molair every day for the last two weeks. At the beginning of 
the third week you get a headache.’ They were then asked two questions: 
1) Symptom misattribution: 
What do you think is the most probable reason for this?” Participants had a choice 
between five different options (side effect of Molair, onset of a cold, eyestrain, stress, no 
particular reason). Symptom misattribution was defined as indicating “side effect of Molair” as 
most likely reason for the headache symptom.  
2) Behavioural intention to stop treatment: 
Participants indicated which action(s) they would take following the start of the headache 
(stop taking Molair, speak to a doctor or pharmacist, take over the counter painkiller, rest, other, 
none of the above). Participants could select as many options as they wished and could specify 
additional actions. Behavioural intention was operationalised as selecting “stop taking Molair”. 
 
Beliefs about Medicines Questionnaire (BMQ) (26) 
Participants’ beliefs about Molair were assessed with the BMQ-Specific and general 
beliefs about pharmaceutical medicines as a class of treatment were assessed using the BMQ-
General.  
The BMQ-Specific comprises two scales assessing beliefs about the necessity of a 
specific treatment for controlling an illness (5 items e.g. “My health, at present depends on 
Molair”) and concerns about potential adverse consequences of taking it (6 items e.g. “Having to 
take Molair worries me”). The scales are validated (23, 26). 
The BMQ-General comprises three 4-item scales assessing views about pharmaceutical 
medicines as a class of treatment. The General Harm scale assesses beliefs about the degree 
to which medicines are essentially harmful (e.g. “Medicines do more harm than good.”). The 
General Overuse scale assesses beliefs about whether doctors place too much emphasis and 
trust on medicines (e.g. “If doctors had more time with patients they would prescribe fewer 
medicines.”). The General Benefit scale assesses beliefs about the degree to which medicines 
are fundamentally beneficial (e.g. “Medicines help many people live better lives.”).  
All BMQ items were rated on 5-point Likert-type scales (1=strongly disagree to 5=strongly 
agree). Scale scores were computed by summing item scores within each scale and dividing it 
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by the number of scale items. Higher scores indicate stronger endorsement of scale constructs 
(range 1-5). The internal consistency of the BMQ-Specific (Cronbach’s αs: Molair 
Necessity=.88, Molair Concerns=.84) and BMQ-General was good (Cronbach’s αs: General 
Harm=.75, General Overuse=.77 and General Benefit=.91).  
 
Perceived Sensitivity to Medicines Scale (PSM) 
The PSM is a validated scale (57) which assesses beliefs about self in relation to 
medicines; specifically about personal sensitivity to medicines. The scale has 5 items (e.g. “My 
body overreacts to medicines.”), which are rated on 5 point Likert-type scales (1=strongly 
disagree to 5=strongly agree). The PSM score was computed by dividing the total scale score 
by the number of scale items. Internal reliability was excellent (Cronbach’s α=.91). 
 
Measures to assess fidelity of PIL information variations (Efficacy and Side Effect VAS) 
Visual analogue scales (VAS) were included to check whether PIL variations changed 
perceptions of Molair. Four VAS assessed side effect perceptions (e.g. “How frequently do you 
think people in general develop side effects when taking Molair?” rated from 0=never to 
100=always). Three VAS measured efficacy perceptions (e.g. “How effective do you think Molair 
is in general for the prevention of asthma symptoms?” rated from 0=not effective at all to 
100=extremely effective). Mean scores were computed for both sets of VAS. Internal 
consistency was high for both VAS sets (Cronbach’s αs of .88 and .90 respectively) 
 
Positive and Negative Affect Schedule (PANAS)  
State Negative Affect was assessed with the short form of the PANAS (58) with 
instructions to focus on current feelings. Ten negative (e.g. distressed, upset) adjectives were 
rated on 5-point Likert scales (1=not at all to 5=extremely). State Negative Affect (State 
NAPANAS) scores were computed by averaging scores for all negative adjectives. Internal 
consistency was high (Cronbach’s α=.95). 
 
State and Trait Anxiety Inventory (STAI) 
The STAI Form X (59) was used to measure State (State NASTAI: 20-State Negative Affect 
items e.g. “I am tense.”) and Trait Negative Affect (Trait NA STAI 20-items e.g. “I worry too much 
over something that doesn’t matter.”). Items were rated on 4-point Likert scales (1=almost never 
to 4=almost always). Subscale scores were computed by averaging state and trait item scores. 
Internal consistency for both subscales was excellent (both Cronbach’s α=.91). 
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Demographics and reported asthma diagnosis 
Participants were asked to state their gender, age, country of residence, first language and 
to indicate whether they had ever been diagnosed with asthma (henceforth ‘reported asthma 
diagnosis’).  
 
Procedures  
The study was exempt from REC approval as confirmed by the UCL Research Ethics 
Committee.  
Data was collected using Qualtrics online software (60). After giving informed consent, 
participants completed the PANAS and STAI (wave 3 only, see Figure 1), PSM and BMQ 
General. Next they received information about asthma and were randomised to receive the 
different PILs using the computerized block randomization function in Qualtrics. The order of 
side effects in the PILs was determined through simple computerized randomization in 
Qualtrics. 
After reading the information, participants completed the Efficacy and Side Effect VAS and 
BMQ-Specific, and brief memory tasks (reported elsewhere). Finally, they completed the 
symptom misattribution and behavioural intention measure, and demographic questions. After 
completing the study, participants received a short written debriefing statement. It took 
participants approximately 14 minutes to complete the study. 
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Figure 1: Overview of Procedures  
 
 
Note. PANAS=Positive and Negative Schedule; STAI=Stat Trait Anxiety Inventory; 
PSM=Perceived Sensitivity to Medicines Scale; BMQ=Beliefs about Medicines Questionnaire, 
PIL=Patient Information Leaflet, VAS=Visual Analogue Scale 
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Sample size and statistical analysis 
The sample size needed to detect an association between medication beliefs and 
symptom misattribution was calculated using GPower v3.1. An estimated odds ratio of 1.57, 
based on the reported association between BMQ Concern scores and side effect reports in a 
large US online sample (61) was used to ascertain that 251 participants were needed to detect 
this univariable association with 80% power and a two-tailed alpha error probability of .05.  
Two checks were conducted to assess the validity of the model. Independent t-tests 
assessed whether PIL variations changed Side Effect /Efficacy VAS ratings and specific 
medication beliefs. Associations between general and specific medication beliefs and perceived 
sensitivity to medicines were examined with Pearson correlations. 
Univariate logistic regression, t-tests and chi-square tests were used to explore whether 
symptom misattribution and behavioural intention were associated with general and specific 
medication beliefs, affect, demographic variables, reported asthma diagnosis, and PIL 
variations. Hierarchical logistic regression models tested for the effect of medication beliefs on 
both outcomes when controlling for PIL variations, affect and demographics in the models. We 
also used moderation analysis to test whether the relationship between medication beliefs and 
both outcomes was similar for people with and without reported asthma diagnosis and across 
PIL variations. Results of logistic regression models are reported using odds ratios (ORs), which 
reflect the change in odds of the outcome associated with a 1-unit change in the predictor. ORs 
above 1 indicate the outcome is more likely, ORs below 1 indicate the outcome is less likely. An 
OR of 1.5 constitutes a small, 3.5 a medium, and 9 a large effect size (62). Classification tables 
and the Hosmer Lemeshow Test (HLT) assessed adequacy of model fit.  
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Results 
 
Survey completion rates and data exclusions 
We obtained 782 responses. Repeated responses from the same computer (n=26), 
responses from underage participants (n=2), and responses with missing data on the two main 
dependent variables were excluded (n=64). Medication beliefs did not differ between completers 
and noncompleters (ps>.05). Responses from 690 participants (wave 1=201, wave 2=249, 
wave 3=240) were retained. 
 
Demographic characteristics and reported asthma diagnosis 
Approximately two-thirds of respondents were female and around a third reported a past 
asthma diagnosis. Participants were mainly US residents (all other countries <1) and native 
English speakers (see Table I). 
 
Main outcomes: Symptom misattribution and behavioural intention frequencies 
Around a fourth of participants (n=170, 24.6%) misattributed the headache as a side effect 
and 69 (40.6%) of these said that they would stop taking Molair as a result. Univariate logistic 
regression showed that misattribution significantly increased behavioural intention to stop the 
treatment (OR=8.02, 95% CI[4.69, 10.69], p<.001). Frequencies of symptom misattribution were 
similar in the different PIL conditions (χ2(3)=3.80, p=.29), ranging from 20.4% (n=21) in the 
“Moderate Efficacy PIL” condition to 28.7%(n=70) in the “High Efficacy PIL” condition. There 
was also no difference in behavioural intention between PIL conditions (χ2(3)=0.37, p=.95). 
Participants who reported an asthma diagnosis did not differ in rates of symptom misattribution 
(n = 57, 25.56%) and behavioural intention (n=25, 11.21%) from those who did not (n=113, 
24.30% and n=44, 9.50 % respectively; both p>.48). Symptom misattribution and behavioural 
intention rates were similar for men and women. We did find a significant effect of age, with 
older participants being less likely to attribute the headache as a side effect and subsequently 
intend to stop the medication (see Table II). 
 
Between group comparisons of medication beliefs and Efficacy/Side Effect VAS 
Molair Necessity was higher for participants who were randomized to the “High Efficacy” 
(M=3.06, SD=0.78) compared to the “Moderate Efficacy” PIL (M=2.78, SD=0.73, t(199)=2.60, 
p<.01). Molair Concerns were higher for participants who saw the “High Side Effect Frequency” 
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(M=3.10, SD=0.83) compared to the “Low Side Effect Frequency” PIL (M=2.90, SD=0.83, 
t(487)=2.59, p<.01). All PIL variations affected Efficacy and Side Effect VAS in the expected 
direction: Side Effect VAS scores were higher in the “High Side Effect Frequency” than in the 
“Low Side Effect Frequency” PIL conditions, and Efficacy VAS scores were higher in the “High 
Efficacy” than in the “Moderate Efficacy” PIL condition (all ts>6.2, ps<.001). Independent t-tests 
demonstrated no significant differences between participants with and without reported asthma 
diagnosis in general and specific medication beliefs (ps>.05). Participants with a reported 
asthma diagnosis perceived themselves to be more sensitive to the effects of medicines 
(M=2.72, SD=1.05) than those without (M=2.47, SD=0.97; t(685)= 3.05, p<.01). 
 
Inter-correlations medication belief scales 
Concerns about Molair were significantly positively correlated with individuals’ perceptions 
of medicines as generally harmful (r=.371) and over-prescribed by doctors (r=.382). Participants 
with stronger benefit beliefs showed reduced Molair Concerns (r=-.101) and higher Molair 
Necessity beliefs (r=.260). Perceptions of higher personal sensitivity to medicines were 
significantly positively correlated with beliefs that medicines are fundamentally harmful (r=.247) 
and overprescribed (r=.198) as well as Molair Concerns (r=.259, all ps<.01, two-tailed). 
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Table I: Sample characteristics  
 
Wave 1 
Efficacy 
information 
variation 
(N=201) 
Wave 2 
Side effect 
likelihood 
variation 
(N=249) 
Wave 3 
Side Effect 
Likelihood 
variation with 
affect measures 
(N=240) 
Waves 1-3 
combined 
 
(N=690) 
P-values 
Age in years mean (SD) 34.8 (12.6) 36.2 (11.6)a 37.27 (14.2)c 36.16 (12.8) p=.127 
Gender n (%) 
   
  
   Male 77 (38.3) 73 (29.3) 86 (36.0)a 236 (34.3) p=.106 
   Female 124 (61.7) 176 (70.7) 153 (64.0) 453 (65.7)  
Race n (%) 
   
  
   White American 124 (61.7) 169 (67.9) 147 (61.5)a 440 (63.9) p=.156 
   White British/ Irish 17 (8.5) 20 (8.0) 12 (5.0) 49 (7.1)  
   Black 14 (7.0) 25 (10.0) 27 (11.3) 66 (9.7)  
   
Indian/Pakistani/Banglades
hi 
18 (9.0) 11 (4.4) 15 (6.3) 44 (6.4) 
 
   Other 28 (13.9) 24 (9.6) 38 (15.9) 90 (13.1)  
First Language n (%) 
   
  
   English 191 (95.5)a 234 (94.4)a 220 (91.7) 645 (93.8) p=.226 
Country of residence       
  United States n (%) 200 (99.5) 226 (91.9) 222 (94.1) 648 (94.9) p=.219 
Asthma n (%)d 
   
  
   reported diagnosis 73 (36.3) 69 (27.7) 81 (34.0)b 223 (32.4) p=.123 
 
Note. a 1 missing value; b 2 missing values; c 4 missing values; d self-reported past asthma 
diagnosis; SD=standard deviation; p-values refer to Chi-Square tests between waves (with the 
exception of age: Univariate ANOVA) 
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Regression analyses examining the association between medication beliefs and 
symptom misattribution/behavioural intention 
Univariable logistic regression was used to explore whether misattribution and behavioral 
intention were associated with general and specific medication beliefs. People who had more 
negative general and specific medication beliefs were more likely to misattribute headache as a 
side effect and intend to stop taking Molair. General Harm, General Overuse and Molair 
Concerns increased the odds of symptom misattribution and behavioural intention. General 
Benefit and Molair Necessity reduced the odds of both outcomes. PSM was not associated 
symptom misattribution and behavioural intentions (see Table II).  
We then constructed two hierarchical logistic regression models to test whether negative 
general and specific medication beliefs predicted symptom misattribution and behavioural 
intention when entered jointly into the model (see Table III, Figure 2). We included 
demographics (age, gender), asthma diagnosis and PIL variations as control variables in step 1. 
General medication beliefs and PSM were entered in step 2 and specific medication beliefs in 
step 3. In both models, age, but none of the other control variables, was significantly associated 
with either outcome. In the symptom misattribution model, general medication beliefs 
significantly improved prediction, and adding the specific medication belief block further 
improved prediction. In the full model, General Harm and Molair Concerns increased symptom 
misattribution, while Molair Necessity reduced symptom misattribution. The effect of General 
Overuse was significant at step 2, but not at step 3. In the behavioural intention model, both the 
general and specific medication belief step significantly improved prediction. In the full model, 
General Harm, Molair Necessity and Molair Concerns independently predicted behavioural 
intention. General Benefit was associated with reduced behavioural intention at step 2, but not 
at step 3. Both models had adequate fit as indicated by non-significant HLTs. 
Using wave 3 data, we built hierarchical logistic regression models for both outcomes, 
controlling for negative affect in the first step and adding general and specific medication beliefs 
jointly in the second step. In the model predicting symptom misattribution, the affect block was 
not significant ((X2(3)=3.68, p=.30), while step 2 (general and specific medication beliefs and 
PSM) improved the model considerably (X2(6)=13.51, p<.05; full model X2(9)=17.20, p<.05). 
Molair Necessity was the only significant predictor of misattribution (OR=0.55, 95% 
CI[0.36,0.85]). The model had adequate fit as shown by a non-significant HLT and accounted 
for 77.6% correct classification of cases. In the equivalent model predicting behavioural 
intention, the affect block (X2(3)=2.01, p=.57) was not significant, while the medication belief 
block significantly improved prediction (X2(6)=18.92, p<.01). Only General Harm (OR=3.79, 
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95%CI [1.62,8.90]) was a significant predictor. The full model (X2(9)=20.92, p<.05) had 
adequate fit (HLT p>.05) and accounted for 90.0% correct classification of cases. 
 
Tests for interaction effects 
Hierarchical logistic regression models predicting symptom misattribution and behavioural 
intention were constructed for each medication belief. In these models the medication belief, PIL 
variation and their interaction term were entered in consecutive steps. No significant interaction 
effects between PIL variations and medications beliefs were detected (ps>.05), indicating that 
the relationship between medication beliefs and both outcomes was similar for participants who 
saw the different PILs.  
 
A similar set of regression models was constructed to test for interaction effects between 
medication beliefs and reported asthma diagnosis in predicting these outcomes. In each model 
the medication belief (e.g. General Harm), asthma diagnosis and the interaction term (e.g. 
General Harm x asthma diagnosis) were entered in consecutive steps. None of the interaction 
terms was significant (ps>.05), indicating medication beliefs have similar effects for individuals 
with and without reported asthma.  
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Table II: Univariate logistic regression models predicting symptom misattribution 
and behavioural intention to stop treatment 
 Symptom misattribution   Behavioural intention  
Univariate Predictors OR 95% CI  OR 95% CI 
General Medication Beliefsa      
    General Benefit 0.72** [0.57, 0.91]  0.53*** [0.39, 0.73] 
    General Harm 1.90*** [1.53, 2.37]  2.72*** [2.00, 3.71] 
    General Overuse 1.74*** [1.39, 2.18]  1.56** [1.13, 2.14] 
Specific Medication Beliefsa      
    Molair Necessity 0.72** [0.58, 0.89]  0.70* [0.51, 0.84] 
    Molair Concern 1.52*** [1.21, 1.89]  1.78*** [1.28, 2.47] 
PSM 1.02 [0.86, 1.21]  1.25 [0.98, 1.59] 
Affectb      
    State NA PANAS 1.01 [0.98, 1.05]  1.03 [0.99,1.08] 
    State NA STAI 1.02 [0.99, 1.05]  1.02 [0.97, 1.06] 
    Trait NA STAI 1.02 [1.00, 1.05]  1.02 [0.98, 1.06] 
Demographic factorsa      
    Age 0.98* [0.97, 1.00]  0.96* [0.94, 0.98] 
    Genderc 0.81 [0.57, 1.16]  0.61 [0.37, 1.00] 
Note. OR=Odds ratio; CI=confidence interval; PSM=Perceived Sensitivity to Medicines; NA= 
negative affect; PANAS= Positive and Negative Affect Schedule, STAI = State Trait Anxiety 
Inventory, a N=690, b N=240 (data available for wave 3 only); creference category=male; *p<.05, 
**p<.01, ***p<.001 
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Table IV: Multivariate hierarchical logistic regression models predicting symptom 
misattribution and behavioural intention to stop medication (N=690) 
 Symptom misattribution   Behavioural intention  
 OR 95% CI  OR 95% CI 
Step 1:PIL variation, demographics and asthma diagnosis 
Χ2 Block: Χ2(4)=8.20, p=.09  Χ2(4)=14.76, p<.01 
PIL variation 
Genderb 
Age 
Reported asthma diagnosisc 
1.04 
0.84 
0.98* 
0.94 
[0.94, 1.16] 
[0.59, 1.22] 
[0.97, 1.00] 
[0.65, 1.36] 
 1.04 
0.70 
0.96** 
0.90 
[0.90 , 1.21] 
[0.41, 1.17] 
[0.94, 0.99] 
[0.53, 1.53] 
 
Step 2: General Medication Beliefs and PSM 
Χ2 Block: Χ2(4)=40.30, p<.001  Χ2(4)=50.22, p<.001 
PIL variation 
Genderb 
Age 
Reported asthma diagnosisc 
General Harm 
General Benefit 
General Overuse 
PSM 
1.01 
0.86 
0.98* 
0.99 
1.57** 
0.88 
1.40* 
0.90 
[0.91, 1.13] 
[0.59, 1.27] 
[0.97, 1.00] 
[0.67, 1.46] 
[1.16, 2.12] 
[0.67, 1.14] 
[1.05, 1.89] 
[0.74, 1.09] 
 1.00  
0.81 
0.96** 
1.09 
3.09*** 
0.61** 
0.79 
1.08 
[0.85, 1.17] 
[0.47, 1.41] 
[0.94, 0.99] 
[0.62, 1.92] 
[1.98, 4.80] 
[0.43, 0.88] 
[0.51, 1.22] 
[0.82, 1.43] 
 
Step 3: Specific Medication Beliefs 
Χ2 Block: Χ2(2)=8.81, p<.05  Χ2(2)=6.92 p<.05 
PIL variation 
Genderb 
Age 
Reported asthma diagnosisc 
General Harm 
General Benefit 
General Overuse 
PSM 
Molair Necessity 
Molair Concern 
1.02 
0.86 
0.98* 
1.00 
1.55** 
0.98 
1.28 
0.90 
0.74* 
1.30* 
[0.91, 1.14] 
[0.58, 1.26] 
[0.97, 1.00] 
[0.67, 1.48] 
[1.14, 2.11] 
[0.74, 1.30] 
[0.95, 1.73] 
[0.74, 1.09] 
[0.58, 0.94] 
[1.00, 1.68] 
 1.01 
0.80 
0.96** 
1.12 
3.07*** 
0.71 
0.66 
1.08 
0.69* 
1.50* 
[0.86, 1.19] 
[0.46, 1.40] 
[0.94, 0.99] 
[0.63, 1.98] 
[1.95, 4.82] 
[0.49, .1.04] 
[0.42, 1.05] 
[0.81, 1.43] 
[0.49, 0.97] 
[1.02, 2.20] 
 
Χ2 Total model: 
Hosmer Lemeshow Test: 
Correct classification (%): 
 
Χ2(10)=55.88, p<.001 
Χ2(8)=10.22, p=.25 
75.8 
  
Χ2(10)=71.90, p<.001 
Χ2(8)=6.44, p=.60 
90.2 
Note. OR= odds ratio; CI= confidence interval; PSM=Perceived Sensitivity to Medicines Scale; 
PIL= Patient Information Leaflet a reference category: high efficacy information, b reference 
category: male, c reference category: self-reported past asthma diagnosis;*p<.05, **p<.01, 
***p<.001 
  
Page 19 
 
Figure 2: Hierarchical logistic regression models1 predicting symptom 
misattribution and behavioural intention to stop medication (N=690) 
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Note.  1 adjusted for PIL variation, gender, age and self-reported past asthma diagnosis; 
OR=Odds Ratio, CI=95% Confidence Interval; *p<.05, **p<.01, ***p<.001;  
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Discussion 
 
Using an analogue approach, we have demonstrated that misattribution of symptoms as side 
effects may be common (about a quarter of participants misattributed headache, not listed in the 
PIL, as a medication side effect) and that general and specific medication beliefs predicted 
symptom misattribution. Participants were more likely to misattribute headache as a side effect 
and intend to stop treatment if they initially believed pharmaceutical medication to be generally 
harmful, over-prescribed by doctors, less beneficial, and if they had stronger concerns and more 
doubts about need for Molair. Perceived sensitivity to medicines (PSM) was unrelated to 
misattribution and behavioural intention. However, correlations between PSM and both general 
and specific medication beliefs were consistent with our theoretical model (63). As expected 
from an analogue approach with a hypothetical medication, correlations between the medication 
belief scales were small to moderate in scale (64), yet statistically significant and in the 
predicted direction. The relationship between medication beliefs and symptom misattribution 
and behavioural intention was not affected by manipulations of side effect and efficacy 
descriptions in the PIL and was similar for participants with and without self-reported past 
asthma diagnosis. We further demonstrated that medication beliefs predicted symptom 
misattribution when controlling for negative affect as a potential confounder. 
 
The associations of medication beliefs with symptom misattribution and intention to stop 
treatment detected in this study mirror the associations between medication beliefs, side effect 
reporting and adherence to medication in the clinical literature. Patients with concerns about 
their medication are typically less adherent, while patients with stronger beliefs in the personal 
necessity of medication tend to be more adherent (29). Previous studies also show that patients 
with stronger concerns about their medication (36, 37, 61) and more negative beliefs about 
medicines in general (65) report more side effects. Misattribution of symptoms as medication 
side effects may help to understand part of the relationships between medication beliefs, side 
effect reports and adherence. Patients often experience a range of disease symptoms and 
sensations from normal bodily function (14, 66). If they have negative beliefs about medicines, 
they may misattribute these symptoms as side effects, thereby reinforcing negative beliefs, 
reducing adherence, and increasing future symptom misattribution. The size of the associations 
between medication beliefs and symptom misattribution/behavioural intentions in this study 
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were small to moderate (64), with univariable odds ratios ranging from1.52 to 2.76. An odds 
ratio of 1.52 for the association of Molair Concerns and symptom misattribution indicates that for 
every 1 unit increase in Molair Concerns, the odds that the headache symptom is misattributed 
as a side effect is multiplied by 1.52 (or in other words the predicted odds are increased by 
52%). 
 
Symptom misattribution is one of several (not mutually exclusive) processes that might 
explain the association between negative medication beliefs and side effect reporting in clinical 
groups. Patients with negative beliefs about medication may monitor their body more intensively 
during pharmacological treatment, leading to increased side effect reporting. Several 
experimental studies have shown that merely attending to bodily sensations may increase the 
perceived intensity (67) and frequency (68) of symptoms. Medication beliefs may also influence 
other known nocebo mechanisms (69): patients with negative medication beliefs may form 
negative treatment expectations (70) and be predisposed to develop conditioned nocebo 
responses. Manipulations that are likely to increase concerns about other substances, e.g. 
warnings about chemical pollution, have been found to increase conditioned learning of somatic 
symptoms (71). Patients with high concerns may be more likely to learn the association 
between medication cues and side effect responses, 
 
Medication beliefs are part of a complex of psychological factors that may affect side effect 
reporting. Individuals with high negative affect report more symptoms (72-74) and side effects 
(75, 76). Concerns about medication have also been associated with negative affect (77). 
Negative affect may confound the relationship between medication beliefs and side effect 
attributions. This was not confirmed by our analysis, where the relationship between negative 
medication beliefs and concerns and side-effect misattribution was independent of negative 
effect. Other psychological factors such as Type A personality (78), somatization, depression 
(79), somatosensory amplification (75), pessimism (17) and alexithymia (80) (inability to identify 
and describe emotions) have been linked to side effect reporting to both active medication and 
placebo and could plausibly be associated with misattribution processes and concerns. These 
factors merit investigation in future studies. 
 
There are several limitations of this analogue study using online recruitment. Our findings 
may not generalize to clinical settings, where patients have a medically confirmed diagnosis, co-
morbid conditions, take active medication and experience illness symptoms (81)). Due to the 
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nature of the online sampling procedure (82) relatively few participants in the older age segment 
(e.g.>65) and thus less likely to have been pre-exposed to medical conditions and medication 
use. Participants also may not have fully understood the information they received about the 
hypothetical drug. Research on health literacy suggests that patients’ understanding of health 
information is also far from perfect in general practice (83). It will however be interesting to 
explore whether patients who do not fully understand (or chose not to read) patient information 
rely more on their underlying general attitudes and beliefs when making symptom attributions. 
Our confidence in the external validity of the analogue approach is strengthened by findings 
from research in patients with medically unexplained symptoms using a similar approach to 
study symptom attribution (84). In the extensively used Symptom Interpretation Questionnaire 
(85), patients read about various common symptoms and are asked to select between different 
causal explanations. Patients who attribute these symptoms more to somatic and psychological 
factors tend to report more symptoms than patients who make normalizing attributions (85).  
 
Despite its limitations, this study extends our understanding of side effect attributions and 
the role of general and specific beliefs about medicines in this process. The findings have 
potential clinical implications. Understanding patients’ medication beliefs may help identify 
patients at risk of misattributing unrelated symptoms as side effects and aid the interpretation of 
side effect reports in RCTs and clinical practice. Medication beliefs are modifiable through 
cognitive-behavioural interventions (86). Potentially interventions to modify beliefs about 
medicines could therefore reduce non-specific side effects and related nonadherence.  
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Appendix A: Asthma background information 
 
What is asthma? 
Asthma is caused by inflammation of the airways. These are the small tubes, called 
bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed 
and more sensitive than normal. 
When you come into contact with something that irritates your lungs, known as a trigger, 
your airways become narrow, the muscles around them tighten and there is an increase in the 
production of sticky mucus (phlegm). This leads to symptoms including: 
 difficulty breathing 
 wheezing and coughing 
 a tight chest 
Asthma symptoms flare up from time to time and there may be no apparent reason why. 
However, some people find that symptoms are made worse by triggers such as exercise, 
fumes, and pollen. These things cause your body to produce chemical substances called 
leukotrienes, which cause inflammation. 
1 in 12 people in the United States suffer from asthma.  
 
Treating asthma 
While there is no cure for asthma, there are a number of treatments that can help control 
the condition. Treatment is based on two important goals: 
-relieving symptoms  
-preventing future symptoms and attacks from developing 
 
Treatment and prevention involves a combination of medicines, lifestyle advice and 
identifying and then avoiding potential asthma triggers. 
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Appendix B: Molair Patient Information Leaflets 
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